D

espite impressions to the contrary, federal officials plan to pursue drug makers for illegal marketing, according to one Department of Justice official who recently provided a roadmap for those seeking to identify bad behavior.

At issue is off-label marketing, a contentious topic that has resulted in huge fines paid by numerous drug makers over the years and is now at the center of a free speech struggle between the pharmaceutical industry and the Food and Drug Administration.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy